INTRODUCTION: The aim of the study was to disclose information about the recently incorporated bisphosphonates therapies used to treat prostate cancer patients and their potential risks because the chemical nature and nitrogen content varies among the available drugs on the market.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
PATIENTS AND METHODS: Three hundred twenty-four consecutive prostate cancer patients were submitted to bisphosphonates therapy after antiandrogen treatment was started. Zoledronic acid was administered monthly (n = 45), bimonthly (n = 15), trimonthly (n = 19), and semestrally (n = 15), and monthly intravenous clodronate was administered in an additional 156 cases. Fourteen additional cases switched the drugs during the course of the treatment.
RESULTS: After a median follow-up of 54 ± 24 (control), 63 ± 7 (clodronate), and 54 ± 6 months (zoledronic acid), the only 2 patients (0.6%) who developed osteonecrosis of the jaw (ONJ) occurred in those who switched the drug.
CONCLUSION: This study is the longest and the largest ever reported on bisphosphonates usage in prostate cancer patients. ONJ seems to be exclusively related to nitrogen content bisphosphonates.
Rodrigues P, Hering F, Imperio M. Are you the author?
Urology Clinic, Hospital Beneficência Portguesa of São Paulo, São Paulo, Brazil; Urology Department, Hospital Santa Helena of São Paulo, São Paulo, Brazil.
Reference: Clin Genitourin Cancer. 2014 Oct 23. pii: S1558-7673(14)00231-6.